統合失調症の世界市場レポート 2025年

統合失調症の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.4％で75億4,000万米ドルに成長します。予測期間の成長は、個別化医療の拡大、デジタルヘルスソリューションの成長、抗精神病薬の改善、ヘルスケアサービスへのアクセス拡大などに起因しています。予測期間の主な動向には、新薬開発、早期介入重視の高まり、回復志向のケア、統合失調症治療の臨床試験パイプラインの拡大などがあります。

精神疾患の有病率の増加は、今後の統合失調症市場の拡大に拍車をかけると予想されます。精神疾患は、人の認知、感情、気分、行動に影響を与え、日常生活や対人関係に大きな影響を与える幅広い精神衛生状態を包含します。精神疾患患者の増加は、統合失調症の治療における進歩や新薬の開発に拍車をかけ、市場の成長に寄与しています。例えば、2023年3月現在、米国の保健福祉サービス部門である国立精神衛生研究所（NIMH）のデータによると、18歳以上の成人で何らかの精神疾患（AMI）を経験したことのある人は推定5,780万人で、米国の全成人の22.8％を占めています。年齢層別では、18～25歳の若年成人のAMI有病率が33.7％と最も高く、次いで26～49歳（28.1％）、50歳以上（15.0％）でした。このように、精神疾患の有病率の増加が統合失調症市場の成長の原動力になると予想されます。

不安治療に対する需要の高まりが、今後の統合失調症市場の成長を牽引すると予測されます。不安治療は、個人が過剰で衰弱させる不安症状を管理・緩和できるように設計されたさまざまな治療アプローチや介入を包含します。この治療は、統合失調症にしばしば併存する不安症状に対処し、幻覚や妄想などの精神病症状の強度を軽減するのに役立つため、統合失調症患者にとって特に有益です。例えば、2024年5月、米国を拠点とする心理学者の専門組織である米国精神医学会の報告によると、2024年には成人の43％が不安を感じるようになったと報告し、2023年の37％、2022年の32％から増加しており、不安レベルが着実に上昇していることが示されています。したがって、不安治療に対する需要の高まりが統合失調症市場の拡大に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の統合失調症市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の統合失調症市場：成長率分析
• 世界の統合失調症市場の実績：規模と成長、2019～2024年
• 世界の統合失調症市場の予測：規模と成長、2024～2029年、2034年
• 世界の統合失調症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の統合失調症市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 緊張型統合失調症
• 妄想型統合失調症
• 未分化統合失調症
• ヘベフレニック統合失調症
• 残余統合失調症
• その他
• 世界の統合失調症市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 第一世代抗精神病薬
• 第二世代抗精神病薬
• 第三世代抗精神病薬
• 心理療法
• その他
• 世界の統合失調症市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 注射剤
• 世界の統合失調症市場：緊張型統合失調症のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 蝋屈症
• 昏迷
• 興奮状態
• 緊張性興奮
• 世界の統合失調症市場：妄想型統合失調症のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 迫害妄想
• 幻聴
• 妄想性思考
• 世界の統合失調症市場：未分化統合失調症のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 他のタイプに特有ではない症状
• 統合失調症の混合症状
• 世界の統合失調症市場：ヘベフレニック統合失調症（混乱型統合失調症）のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 無秩序な行動
• 無秩序な発言
• 感情の平坦さ
• 世界の統合失調症市場：残存統合失調症のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 軽度の症状を伴う統合失調症の病歴
• 社会的ひきこもり
• 軽度の幻覚または妄想
• 世界の統合失調症市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 統合失調感情障害
• 短期精神病性障害
• 妄想性障害

第7章 地域別・国別分析

• 世界の統合失調症市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の統合失調症市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 統合失調症市場：競合情勢
• 統合失調症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company
• Eli Lilly and Company
• Gilead Sciences Inc.
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• Otsuka Holdings Co. Ltd.
• Biogen Inc.
• Daiichi Sankyo Co. Ltd.
• Astellas Pharma Inc.
• Sumitomo Dainippon Pharma Co. Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Recordati SpA
• Lundbeck A/S

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 統合失調症市場2029：新たな機会を提供する国
• 統合失調症市場2029：新たな機会を提供するセグメント
• 統合失調症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Schizophrenia is a severe and long-term mental illness that significantly affects an individual's cognitive processes, emotional expression, behavior, and their perception of reality. Symptoms may include delusions, hallucinations, disordered speech, and unusual movements. The comprehensive management of schizophrenia involves a combination of pharmaceutical treatments, rehabilitation programs, and supportive services.

Schizophrenia can manifest in different forms, including catatonic schizophrenia, paranoid schizophrenia, undifferentiated schizophrenia, hebephrenic schizophrenia, residual schizophrenia, and others. Catatonic schizophrenia is a subtype characterized by severe motor disturbances, such as catatonia, immobility, and abnormal postures or movements. Treatment typically involves antipsychotic medications and supportive therapies to manage psychotic symptoms and address catatonic motor behavior. Available treatments encompass first-generation antipsychotics, second-generation antipsychotics, third-generation antipsychotics, psychotherapies, and other therapeutic drugs that can be administered through oral or injectable routes.

The schizophrenia market research report is one of a series of new reports from The Business Research Company that provides schizophrenia market statistics, including schizophrenia industry global market size, regional shares, competitors with a schizophrenia market share, detailed schizophrenia market segments, market trends, and opportunities and any further data you may need to thrive in the schizophrenia industry. This schizophrenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The schizophrenia market size has grown strongly in recent years. It will grow from $5.82 billion in 2024 to $6.11 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to growing demand for effective treatments, mental health awareness, government initiatives, growing research and development.

The schizophrenia market size is expected to see strong growth in the next few years. It will grow to $7.54 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to growing personalized medicine, growing digital health solutions, growing improved antipsychotic medications, expanding access to healthcare services. Major trends in the forecast period include new drug development, growing emphasis on early intervention, recovery-oriented cares, expanding clinical trials pipeline for schizophrenia treatments.

The growing prevalence of mental illness is expected to fuel the expansion of the schizophrenia market in the future. Mental illness encompasses a broad spectrum of mental health conditions that impact a person's cognition, emotions, mood, and behavior, significantly affecting their daily life and interpersonal relationships. The rise in mental health cases has spurred advancements in the treatment of schizophrenia and the development of new medications, thereby contributing to the market's growth. For instance, as of March 2023, data from the National Institute of Mental Health (NIMH), a department of health and human services in the United States, indicated that an estimated 57.8 million adults aged 18 and older had experienced any mental illness (AMI), constituting 22.8% of all adults in the United States. Among different age groups, young adults aged 18-25 years exhibited the highest prevalence of AMI at 33.7%, followed by those aged 26-49 years (28.1%), and individuals aged 50 and above (15.0%). Consequently, the escalating burden of mental illness is expected to be a driving force behind the growth of the schizophrenia market.

The increasing demand for anxiety treatment is expected to drive the growth of the schizophrenia market in the future. Anxiety treatment encompasses various therapeutic approaches and interventions designed to help individuals manage and alleviate excessive and debilitating anxiety symptoms. This treatment can be particularly beneficial for those with schizophrenia, as it addresses comorbid anxiety symptoms that often accompany the disorder and can help reduce the intensity of psychotic symptoms such as hallucinations and delusions. For example, in May 2024, a report by the American Psychiatric Association, a U.S.-based professional organization for psychologists, indicated that in 2024, 43% of adults reported feeling more anxious, up from 37% in 2023 and 32% in 2022, showing a steady rise in anxiety levels. Therefore, the growing demand for anxiety treatment is contributing to the expansion of the schizophrenia market.

Prominent companies in the schizophrenia market are embracing emerging technologies like automated psychological therapy to bolster their market presence. Automated psychological therapy involves utilizing technology, including virtual reality (VR), to offer psychological therapy in an autonomous or self-guided manner. For example, in April 2022, OxfordVR Limited, a digital therapeutic company based in Switzerland, introduced the gameChangeVR technology-a 6-week automated VR treatment that delivers cognitive behavioral therapy (CBT) within secure and immersive virtual environments. This VR-based automated psychological therapy replaces real-life therapists with a virtual coach, enabling the treatment to reach a broader range of patients. Notably, this marks the first instance where digital therapy of any kind has demonstrated efficacy in treating individuals with schizophrenia and mood disorders who experience psychotic symptoms.

In March 2023, Royalty Pharma PLC, a US-based purchaser of biopharmaceutical royalties, completed the acquisition of the royalty rights for the KarXT schizophrenia treatment from Karuna Therapeutics Inc., for a sum of $500 million. As part of this agreement, Royalty Pharma will provide PureTech with a 3% royalty on Karuna's annual sales, up to $2 billion. This acquisition also provides PureTech with additional capital to advance its internal pipeline, including ongoing clinical initiatives, with the potential for future commercialization. KarXT is an investigational oral medication specifically developed for the treatment of schizophrenia and other neurological disorders, focusing on M1/M4-preferred muscarinic agonists. Karuna Therapeutics Inc., a clinical-stage biopharmaceutical company based in the United States, specializes in the development of pharmaceuticals for psychiatric disorders and schizophrenia.

Major companies operating in the schizophrenia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Otsuka Holdings Co. Ltd., Biogen Inc., Daiichi Sankyo Co. Ltd., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Recordati SpA, Lundbeck A/S, Neurocrine Biosciences Inc., Torrent Pharmaceutical Ltd., Alkermes PLC, Indivior PLC, Vanda Pharmaceuticals Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., PsychoGenics Inc., Karuna Therapeutics Inc., Minerva Neurosciences Inc.

North America was the largest region in the schizophrenia market in 2024. The regions covered in the schizophrenia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the schizophrenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The schizophrenia market consists of revenues earned by entities by providing cognitive behavioral therapy, electroconvulsive therapy, and group counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The schizophrenia market also includes sales of risperdal, invega, zyprexa, geodon and seroquel. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Schizophrenia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on schizophrenia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for schizophrenia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The schizophrenia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Catatonic Schizophrenia; Paranoid Schizophrenia; Undifferentiated Schizophrenia; Hebephrenic Schizophrenia; Residual Schizophrenia; Other Types
• 2) By Treatment: First-Generation Antipsychotics; Second-Generation Antipsychotics; Third-Generation Antipsychotics; Psychotherapies; Other Treatments
• 3) By Route of Administration: Oral; Injectables
• Subsegments:
• 1) By Catatonic Schizophrenia: Waxy Flexibility; Stupor; Agitation; Catatonic Excitement
• 2) By Paranoid Schizophrenia: Delusions Of Persecution; Auditory Hallucinations; Paranoid Ideation
• 3) By Undifferentiated Schizophrenia: Symptoms Not Specific To Other Types; Mixed Symptoms Of Schizophrenia
• 4) By Hebephrenic Schizophrenia (Disorganized Schizophrenia): Disorganized Behavior; Disorganized Speech; Emotional Flatness
• 5) By Residual Schizophrenia: History Of Schizophrenia With Low-Level Symptoms; Social Withdrawal; Mild Hallucinations Or Delusions
• 6) By Other Types: Schizoaffective Disorder; Brief Psychotic Disorder; Delusional Disorder
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; AbbVie Inc.; Novartis AG; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Schizophrenia Market Characteristics

3. Schizophrenia Market Trends And Strategies

4. Schizophrenia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Schizophrenia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Schizophrenia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Schizophrenia Market Growth Rate Analysis
• 5.4. Global Schizophrenia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Schizophrenia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Schizophrenia Total Addressable Market (TAM)

6. Schizophrenia Market Segmentation

• 6.1. Global Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Catatonic Schizophrenia
• Paranoid Schizophrenia
• Undifferentiated Schizophrenia
• Hebephrenic Schizophrenia
• Residual Schizophrenia
• Other Types
• 6.2. Global Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-Generation Antipsychotics
• Second-Generation Antipsychotics
• Third-Generation Antipsychotics
• Psychotherapies
• Other Treatments
• 6.3. Global Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectables
• 6.4. Global Schizophrenia Market, Sub-Segmentation Of Catatonic Schizophrenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Waxy Flexibility
• Stupor
• Agitation
• Catatonic Excitement
• 6.5. Global Schizophrenia Market, Sub-Segmentation Of Paranoid Schizophrenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Delusions Of Persecution
• Auditory Hallucinations
• Paranoid Ideation
• 6.6. Global Schizophrenia Market, Sub-Segmentation Of Undifferentiated Schizophrenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Symptoms Not Specific To Other Types
• Mixed Symptoms Of Schizophrenia
• 6.7. Global Schizophrenia Market, Sub-Segmentation Of Hebephrenic Schizophrenia (Disorganized Schizophrenia), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Disorganized Behavior
• Disorganized Speech
• Emotional Flatness
• 6.8. Global Schizophrenia Market, Sub-Segmentation Of Residual Schizophrenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• History Of Schizophrenia With Low-Level Symptoms
• Social Withdrawal
• Mild Hallucinations Or Delusions
• 6.9. Global Schizophrenia Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Schizoaffective Disorder
• Brief Psychotic Disorder
• Delusional Disorder

7. Schizophrenia Market Regional And Country Analysis

• 7.1. Global Schizophrenia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Schizophrenia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Schizophrenia Market

• 8.1. Asia-Pacific Schizophrenia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Schizophrenia Market

• 9.1. China Schizophrenia Market Overview
• 9.2. China Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Schizophrenia Market

• 10.1. India Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Schizophrenia Market

• 11.1. Japan Schizophrenia Market Overview
• 11.2. Japan Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Schizophrenia Market

• 12.1. Australia Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Schizophrenia Market

• 13.1. Indonesia Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Schizophrenia Market

• 14.1. South Korea Schizophrenia Market Overview
• 14.2. South Korea Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Schizophrenia Market

• 15.1. Western Europe Schizophrenia Market Overview
• 15.2. Western Europe Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Schizophrenia Market

• 16.1. UK Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Schizophrenia Market

• 17.1. Germany Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Schizophrenia Market

• 18.1. France Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Schizophrenia Market

• 19.1. Italy Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Schizophrenia Market

• 20.1. Spain Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Schizophrenia Market

• 21.1. Eastern Europe Schizophrenia Market Overview
• 21.2. Eastern Europe Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Schizophrenia Market

• 22.1. Russia Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Schizophrenia Market

• 23.1. North America Schizophrenia Market Overview
• 23.2. North America Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Schizophrenia Market

• 24.1. USA Schizophrenia Market Overview
• 24.2. USA Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Schizophrenia Market

• 25.1. Canada Schizophrenia Market Overview
• 25.2. Canada Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Schizophrenia Market

• 26.1. South America Schizophrenia Market Overview
• 26.2. South America Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Schizophrenia Market

• 27.1. Brazil Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Schizophrenia Market

• 28.1. Middle East Schizophrenia Market Overview
• 28.2. Middle East Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Schizophrenia Market

• 29.1. Africa Schizophrenia Market Overview
• 29.2. Africa Schizophrenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Schizophrenia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Schizophrenia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Schizophrenia Market Competitive Landscape And Company Profiles

• 30.1. Schizophrenia Market Competitive Landscape
• 30.2. Schizophrenia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Schizophrenia Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. GlaxoSmithKline PLC
• 31.3. Takeda Pharmaceutical Company
• 31.4. Eli Lilly and Company
• 31.5. Gilead Sciences Inc.
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. Amgen Inc.
• 31.8. Otsuka Holdings Co. Ltd.
• 31.9. Biogen Inc.
• 31.10. Daiichi Sankyo Co. Ltd.
• 31.11. Astellas Pharma Inc.
• 31.12. Sumitomo Dainippon Pharma Co. Ltd.
• 31.13. Mitsubishi Tanabe Pharma Corporation
• 31.14. Recordati SpA
• 31.15. Lundbeck A/S

32. Global Schizophrenia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Schizophrenia Market

34. Recent Developments In The Schizophrenia Market

35. Schizophrenia Market High Potential Countries, Segments and Strategies

• 35.1 Schizophrenia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Schizophrenia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Schizophrenia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer